Companies
- Companies
- Company details
Ambrilia Biopharma Inc
Out-licensing
NGR-Delivery Technology for the Delivery of Anti-cancer Drugs and siRNAs for the Treatment of Cancer
NGR-Delivery Technology for the Delivery of Anti-cancer Drugs and siRNAs for the Treatment of Cancer More
Phase I/II Development of Goserelin for the Treatment of Hormone-Resistant Prostate Cancer More
Phase I/II Development of PCK3145 for the Treatment of Hormone-Resistant Prostate Cancer More
Phase III Clinical Development of Octreotide (C2L) for the Treatment of Acromegaly More
Related Reports
Market Research Reports provided by reports.iptechex.com
Nov 2010 - 40 pages - $500
Nov 2010 - 82 pages - $600
Feb 2011 - 32 pages - $125
Jul 2010 - 54 pages - $750
Feb 2011 - 32 pages - $125
Sep 2010 - 22 pages - $99
Nov 2010 - 44 pages - $600
Jun 2010 - 21 pages - $125
Mar 2011 - 28 pages - $125
Nov 2010 - 40 pages - $500
Contact details
Ambrilla Biopharma
Head office
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us